Relmada Therapeutics (RLMD) Consolidated Net Income (2012 - 2026)
Relmada Therapeutics (RLMD) reported Consolidated Net Income of -$18.5 million for Q1 2026, down 4.07% year-over-year from -$19.3 million in Q1 2025, and up 7.24% quarter-over-quarter from -$19.9 million in Q4 2025.
Relmada Therapeutics (RLMD) Consolidated Net Income (2012 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has 15 years of Consolidated Net Income data on file, last reported at -$18.5 million in Q1 2026.
- Consolidated Net Income for Q1 2026 came in at -$18.5 million, down 4.07% year-over-year; the trailing twelve-month figure through Mar 2026 was -$58.4 million (up 23.33% YoY), and the FY2025 annual result was -$57.7 million, up 28.19% from the prior year.
- Consolidated Net Income improved to -$18.5 million in Q1 2026 per RLMD's latest filing, from -$19.9 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at -$9.9 million in Q2 2025 and troughed at -$45.5 million in Q2 2022.
- A 5-year average of -$24.5 million and a median of -$21.9 million in 2024 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2022 and 2025: Consolidated Net Income sank 71.99% in 2022, then surged 54.5% in 2025.
- A 5-year view of Consolidated Net Income shows it stood at -$38.7 million in 2022, then soared by 33.93% to -$25.6 million in 2023, then gained by 27.96% to -$18.4 million in 2024, then slipped by 8.28% to -$19.9 million in 2025, then advanced by 7.24% to -$18.5 million in 2026.
- Business Quant data shows RLMD's Consolidated Net Income at -$18.5 million in Q1 2026, -$19.9 million in Q4 2025, and -$10.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Relmada Therapeutics | 581.07 Mn | 581.07 Mn | - | -18.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.50 Mn |
| Dec 31, 2025 | -19.95 Mn |
| Sep 30, 2025 | -10.08 Mn |
| Jun 30, 2025 | -9.90 Mn |
| Mar 31, 2025 | -17.78 Mn |
| Dec 31, 2024 | -18.42 Mn |
| Sep 30, 2024 | -22.15 Mn |
| Jun 30, 2024 | -17.86 Mn |
| Mar 31, 2024 | -21.93 Mn |
| Dec 31, 2023 | -25.57 Mn |
| Sep 30, 2023 | -21.37 Mn |
| Jun 30, 2023 | -24.66 Mn |
| Mar 31, 2023 | -26.95 Mn |
| Dec 31, 2022 | -38.70 Mn |
| Sep 30, 2022 | -38.74 Mn |
| Jun 30, 2022 | -45.51 Mn |
| Mar 31, 2022 | -38.30 Mn |
| Dec 31, 2021 | -34.18 Mn |
| Sep 30, 2021 | -42.65 Mn |
| Jun 30, 2021 | -26.46 Mn |